BrainsWay (BrainsWay) Additional Paid-In Capital : $140.45 Mil(As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is BrainsWay Additional Paid-In Capital?

BrainsWay's quarterly additional paid-in capital declined from Sep. 2023 ($140.95 Mil) to Dec. 2023 ($140.34 Mil) but then increased from Dec. 2023 ($140.34 Mil) to Mar. 2024 ($140.45 Mil).

BrainsWay's annual additional paid-in capital increased from Dec. 2021 ($137.57 Mil) to Dec. 2022 ($138.15 Mil) and increased from Dec. 2022 ($138.15 Mil) to Dec. 2023 ($140.34 Mil).

BrainsWay Additional Paid-In Capital Historical Data

The historical data trend for BrainsWay's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay Additional Paid-In Capital Chart

BrainsWay Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

93.65

95.14

137.57

138.15

140.34

BrainsWay Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															138.15	140.55	140.95	140.34	140.45

BrainsWay Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

BrainsWay Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of BrainsWay's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BrainsWay (BrainsWay) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (OTCPK:BRSYF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BWAY:USA BWAY:Israel

Address

19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518

Website

https://www.brainsway.com

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.